QQ客服 官方微博 反馈留言

	The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
	Huang, Guanghong; Sun, Xin; Liu, Dapeng; Zhang, Yunfeng; Zhang, Boxiang; Xiao, Guodong; Li, Xiang; Gao, Xiao; Hu, Chenhao; Wang, Meng
刊名	ONCOTARGET
	2018
卷号	9页码:4239-4248
关键词	NSCLC meta-analysis PD-1/PD-L1 Immune checkpoint inhibitor
ISSN号	1949-2553
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2922989
专题	西安交通大学
推荐引用方式 GB/T 7714	Huang, Guanghong,Sun, Xin,Liu, Dapeng,et al. The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis[J]. ONCOTARGET,2018,9:4239-4248.
APA	Huang, Guanghong.,Sun, Xin.,Liu, Dapeng.,Zhang, Yunfeng.,Zhang, Boxiang.,...&Qin, Sida.(2018).The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.ONCOTARGET,9,4239-4248.
MLA	Huang, Guanghong,et al."The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis".ONCOTARGET 9(2018):4239-4248.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。